iBio Statistics
Share Statistics
iBio has 17.04M
shares outstanding. The number of shares has increased by 14.51%
in one year.
| Shares Outstanding | 17.04M |
| Shares Change (YoY) | 14.51% |
| Shares Change (QoQ) | 7.93% |
| Owned by Institutions (%) | 0.08% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 11,350 |
| FTD / Avg. Volume | 1% |
Short Selling Information
The latest short interest is 656.76K, so 3.98% of the outstanding
shares have been sold short.
| Short Interest | 656.76K |
| Short % of Shares Out | 3.98% |
| Short % of Float | 3.98% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.31 and the forward
PE ratio is -0.56.
iBio's PEG ratio is
0.
| PE Ratio | -0.31 |
| Forward PE | -0.56 |
| PS Ratio | 34.22 |
| Forward PS | 121.7 |
| PB Ratio | 0.36 |
| P/FCF Ratio | -0.41 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for iBio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.08,
with a Debt / Equity ratio of 0.21.
| Current Ratio | 4.08 |
| Quick Ratio | 4.08 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | -0.32 |
| Debt / FCF | -0.24 |
| Interest Coverage | -96.71 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $14,062.5 |
| Profits Per Employee | $-1,556,687.5 |
| Employee Count | 16 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -67.65% in the
last 52 weeks. The beta is 1.19, so iBio's
price volatility has been higher than the market average.
| Beta | 1.19 |
| 52-Week Price Change | -67.65% |
| 50-Day Moving Average | 1.71 |
| 200-Day Moving Average | 2.57 |
| Relative Strength Index (RSI) | 30.08 |
| Average Volume (20 Days) | 1,130,925 |
Income Statement
In the last 12 months, iBio had revenue of 225K
and earned -24.91M
in profits. Earnings per share was -6.5.
| Revenue | 225K |
| Gross Profit | 225K |
| Operating Income | -16.63M |
| Net Income | -24.91M |
| EBITDA | -14.02M |
| EBIT | -15.27M |
| Earnings Per Share (EPS) | -6.5 |
Full Income StatementBalance Sheet
The company has 14.21M in cash and 4.46M in
debt, giving a net cash position of 9.75M.
| Cash & Cash Equivalents | 14.21M |
| Total Debt | 4.46M |
| Net Cash | 9.75M |
| Retained Earnings | -313.85M |
| Total Assets | 19.1M |
| Working Capital | 663K |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -18.55M
and capital expenditures -210K, giving a free cash flow of -18.76M.
| Operating Cash Flow | -18.55M |
| Capital Expenditures | -210K |
| Free Cash Flow | -18.76M |
| FCF Per Share | -4.9 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -7392.89% and -11069.78%.
| Gross Margin | 100% |
| Operating Margin | -7392.89% |
| Pretax Margin | -6863.56% |
| Profit Margin | -11069.78% |
| EBITDA Margin | -6231.56% |
| EBIT Margin | -7392.89% |
| FCF Margin | -8339.56% |
